CCChiara Casprini

Chiara Casprini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chiara Casprini has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Mariachiara Bosco

    Unit of Obstetrics and Gynecology, Department of Surgery, Dentistry, Pediatrics, and Gynecology, AOUI Verona, University of Verona, Verona, Italy

    5 shared publications
  • Simone Garzon

    Unit of Obstetrics and Gynecology, Department of Surgery, Dentistry, Pediatrics, and Gynecology, AOUI Verona, University of Verona, Verona, Italy

    5 shared publications
  • Stefano Uccella

    Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, 37126 Verona, Italy

    5 shared publications
  • Irene Porcari

    Unit of Obstetrics and Gynecology, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, AOUI Verona, 37134 Verona, Italy

    3 shared publications
  • Pier Carlo Zorzato

    Unit of Obstetrics and Gynecology, Department of Surgery, Dentistry, Pediatrics, and Gynecology, AOUI Verona, University of Verona, Verona, Italy

    3 shared publications
  • Alberta Ricci

    Unit of Obstetrics and Gynecology, Department of Surgery, Dentistry, Pediatrics, and Gynecology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Piazzale A. Stefani 1, 37125 Verona, Italy

    1 shared publication

Latest Publications

  • Open Access

    Myo-Inositol Versus Inactive Control in Polyendocrine Metabolic Ovarian Syndrome: Systematic Review and Meta-Analysis

    by Simone Garzon, Chiara Casprini, Marcello Mantovani, Irene Porcari, Pier Carlo Zorzato, Mariachiara Bosco, Rosa Maria Laterza, Dario Paladini, Stefano Uccella

    This systematic review aimed to estimate the effects attributable to myo-inositol (MI) compared with inactive comparators across metabolic, endocrine, clinical, and reproductive outcomes in women with polyendocrine metabolic ovarian syndrome (PMOS), and to assess the certainty of evidence. Scopus, PubMed/MEDLINE, Web of Science, and the Cochrane Library were searched from inception to 31 July 2026. Studies evaluating MI, alone or with nonpharmacological components, were eligible. Risk of bias was assessed using RoB 2 and ROBINS-I, research integrity using RIGID/TRACT, and certainty of evidence using GRADE. Thirty-one studies were included (20 RCTs and 11 observational studies). Quantitative synthesis was restricted to low-integrity-risk RCTs comparing MI-containing interventions with inactive comparators. Participant totals varied across outcomes, with pooled analyses including between 70 and 376 participants. MI reduced LH levels (MD, −3.217 mIU/mL; 95% CI, −5.076 to −1.359; high certainty), likely reduced the LH/FSH ratio, and likely increased SHBG levels (moderate certainty). MI may also reduce free testosterone and irregular menses (low certainty). MI likely reduced HOMA-IR (MD, −0.972; 95% CI, −1.538 to −0.405; moderate certainty). When using assisted reproductive technology, MI likely increased clinical pregnancy (OR, 2.767; 95% CI, 1.151–6.651; moderate certainty). Across outcomes, certainty of evidence was frequently limited by small sample sizes, imprecision, and heterogeneity. Effects on several other outcomes remained insufficiently explored, and phenotype-stratified analyses were not feasible because studies did not report outcomes by PMOS phenotype. In conclusion, MI is associated with metabolic, endocrine, and reproductive benefits in PMOS, with certainty varying substantially across outcomes. Larger, phenotype-stratified RCTs with standardized dosing and adequate treatment duration are needed to confirm these findings.

  • Open Access

    Hair Dyes in Pregnancy: A Systematic Review and Meta‐Analysis

    by Stefano Uccella, Chiara Casprini, Giada Scaggiante, Nikolaos Papadopoulos, Pier Carlo Zorzato, Giulia Biancotto, Mariachiara Bosco, Simone Garzon

    Objective: The main objective is to investigate the association between periconceptional or pregnancy exposure to hair dyes and obstetric and pediatric outcomes. Methods: A systematic literature search was conducted in Scopus, PubMed/MEDLINE, Web of Science, and CINAHL Ultimate from database inception to August 31, 2024. Studies were included based on PECO criteria: pregnant women and their newborns (population), exposure to hair dyes during periconception or pregnancy (exposure), no exposure (comparator), and any obstetric or pediatric complication (outcome). After screening 311 records and removing duplicates, 179 abstracts were reviewed, 29 full texts assessed, and 20 observational studies included. Four reviewers assessed bias and extracted data. Meta‐analyses were performed using a random‐effects model when appropriate. Results: Few studies distinguished hair dye types or exposure timing. Periconceptional or pregnancy hair dye exposure was reported to be associated with stillbirth, low birth weight (Pooled OR 2.30; 95% CI 1.24–4.25), and low hormone levels; in the offspring, with allergic rhinitis, leukemia, neuroblastoma (pooled OR 1.79; 95% CI 1.20–2.68), Wilms tumor (pooled OR 6.00; 95% CI 1.22–29.46), germ cell tumors, and membranous ventricular septal defect. No association was observed with asthma (pooled OR 1.19; 95% CI 0.86–1.65), childhood brain tumors (pooled OR 1.06; 95% CI 0.88–1.28), or mental retardation. Based on the GRADE assessment, the certainty of evidence was low or very low. Conclusions: Current observational evidence suggests a potential association between periconceptional or pregnancy exposure to hair dyes and some adverse obstetric and pediatric outcomes. However, given the low and very low certainty of evidence and the retrospective nature of most included studies, these findings are hypothesis‐generating and preclude causal inference. Further prospective studies are needed to confirm these preliminary associations and define the specific chemicals involved.

  • Open Access

    Topical Spermidine Hyaluronate (Spd-HA) in Vulvovaginal Atrophy: A Preliminary Study

    by Irene Porcari, Michela Carena Maini, Carlo Angelo Ghisalberti, Caterina Tezze, Erica Trimarchi, Alessandra Graziottin, Mariachiara Bosco, Chiara Casprini, Simone Garzon, Stefano Uccella

    Background and Objectives: Genitourinary syndrome of menopause (GSM), previously termed vulvovaginal atrophy (VVA), is a prevalent hypoestrogenic condition characterized by genital, sexual, and urinary symptoms. Although hormonal therapies are effective, many women are unwilling or unsuitable to use them. Spermidine hyaluronate (Spd-HA) has been reported to be effective in the treatment of vulvodynia and is currently under investigation for stress urinary incontinence. The aim of this study was to evaluate the efficacy of Spd-HA gel on the signs and symptoms of GSM. Materials and Methods: Five postmenopausal women with GSM presenting with vulvovaginal atrophy were enrolled in this prospective, single-arm, pilot study. They applied Spd-HA gel locally for eight weeks (three times/week for the first 4 weeks, followed by two times/week for the next 4 weeks). Vulvovaginal signs and symptoms were assessed at baseline (V1), 4 weeks (V2), and 8 weeks (V3) using the most bothersome symptoms (MBS), vaginal health index (VHI), and maturation index (MI) and value (MV). Results: Spd-HA gel was associated with MBS score improvement from baseline to week 8 [from (5.00 ± 2.00) to (1.60 ± 1.52)]. VHI score and MI improved from baseline to week 8. Compared to literature data, improvement in MVs obtained in women who received Spd-HA was greater than those obtained by hydrating products, but lower than those observed in women with estrogen or prasterone therapy. Conclusions: This preliminary experience suggests that Spd-HA gel ameliorates the vulvovaginal component of GSM. It may represent a promising non-hormonal option for women with GSM who are unwilling or unsuitable to receive hormonal therapy, warranting confirmation in larger controlled trials.

  • Open Access

    Hydatidiform Mole with Coexisting Normal Pregnancy: A Systematic Review and Individual Participant Data Meta-Analysis

    by Pier Carlo Zorzato, Alberta Ricci, Mariachiara Bosco, Liliana Galli, Laura Luka, Irene Porcari, Rosa Maria Laterza, Veronica Parolin, Michele Milella, Antonio Simone Laganà, et al.

    Background and Objectives: This study aimed to evaluate obstetric, neonatal, and oncologic outcomes of pregnancies complicated by a hydatidiform mole coexisting with a live fetus (HMCF) carried beyond viability, and to assess the impact of delivery mode on outcomes. Materials and Methods: A systematic review and individual participant data meta-analysis included HMCF cases progressing beyond 23 weeks. Obstetric and neonatal outcomes, delivery patterns, and oncologic risks were analyzed. Results: Among 118 pregnancies complicated by HMFC (124 newborns), most were complete moles (87%). Median delivery occurred at 31.6 weeks, with over half before 32 weeks. Common complications included vaginal bleeding (59%), preeclampsia (30%), and hyperthyroidism (18%). Cesarean delivery was performed in 79% of cases, often for mole-related factors, but was not associated with reduced maternal or oncologic risk. Neonatal deaths occurred exclusively in infants delivered ≤32 weeks, highlighting extreme prematurity as the key determinant of survival. Severe preeclampsia was strongly linked to earlier delivery. Conclusions: With close monitoring, continuation of HMCF pregnancies is possible. Neonatal mortality is mainly driven by prematurity, which appears to be an indirect consequence of HMFC through the development of mola-associated complications. Cesarean section does not appear to improve maternal and oncologic outcomes. Vaginal delivery can be considered when no standard contraindications exist.


  • Vulvovaginal estrogen therapy for urinary symptoms in postmenopausal women: a review and meta-analysis

    by Irene Porcari, Stefano Uccella, Chiara Casprini, Mariachiara Bosco, Pier Carlo Zorzato, Simone Garzon

    This study aimed to summarize available evidence on the efficacy of vulvovaginal topical estrogen therapy on lower urinary tract symptoms (LUTS) of genitourinary syndrome of menopause. Multiple databases were systematically searched from inception to October 2024 to identify all studies providing pretreatment and post-treatment data for menopausal women with LUTS who received vulvovaginal estrogen therapy. A random effect meta-analysis was conducted (PROSPERO registration number: CRD42024517516). Seventeen studies were included for a total of 2111 patients. The pooled odds ratio for the occurrence of considered outcomes after versus before treatment was 0.14 (95% confidence interval [CI] 0.05-0.36; I2 = 73%) for recurrent urinary tract infections, 0.12 (95% CI 0.05-0.29; I2 = 62%) for stress urinary incontinence, 0.22 (95% CI 0.16-0.32; I2 = 0%) for urge incontinence, 0.11 (95% CI 0.06-0.18; I2 = 23%) for urgency, 0.22 (95% CI 0.16-0.23; I2 = 0%) for frequency and 0.24 (95% CI 0.17-0.34; I2 = 0%) for nocturia. The pooled mean difference for vaginal pH was -1.29 (95% CI -1.66 to -0.91; I2 = 96%). Vulvovaginal topical estrogen therapy appears to improve all analyzed LUTS in menopausal women. Available evidence supports current guidelines recommending vulvovaginal topical estrogen therapy for the management of these symptoms in menopausal women.


  • Open Access

    Voluntary multifetal pregnancy reduction: who should decide and select, and why?

    by Sara Patuzzo Manzati, Chiara Casprini, Mariachiara Bosco, Ricciarda Raffaelli, Stefano Uccella, Massimo Franchi, Simone Garzon